StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells
Exelixis and StemSynergy Enter Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies
Scientists provide proof of concept for potential new class of cancer drugs
StemSynergy Therapeutics Invited to Present at the NIH SBIR/STTR Innovation Zone at the 2014 BIO International Biotechnology Conference
Cool Springs Life Sciences Center adds new tenant
Stemsynergy announces breakthrough in treating sarcomas with its novel anti-Wnt compound
SSTI has a multidisciplinary team of scientists.
Meet the founders behind StemSynergy Therapeutics, Inc.
SSTI targets cancer stem cell pathways that drive tumor growth.
